Two years after rules overhaul, methadone clinics face federal evaluation

Two years after the federal government overhauled regulations for methadone clinics to allow greater flexibility, data shows a significant shift. According to a survey of 241 clinics, over 70% have adopted changes like expanded take-home doses and optional counseling, which increased three-month patient retention by an average of 17% at some clinics. However, critics like Aaron Ferguson warn of selection bias and geographic disparities, arguing that larger providers and conservative states are lagging behind.

Federal methadone regulation overhaul

• ▪The 2024 federal regulations stressed that counseling should be offered to patients but not required as a condition of receiving methadone medication.
• ▪In 2024, the United States federal government issued an overhaul of regulations determining how specialized methadone clinics operate.
• ▪The 2024 Substance Abuse and Mental Health Services Administration guidelines recommended using drug testing as a clinical decision-making factor rather than automatically punishing patients who test positive.
• ▪The 2024 Substance Abuse and Mental Health Services Administration guidelines eliminated rules requiring patients to have been addicted to opioids for over a year before admission.

Flexible take-home medication policies

• ▪Roughly two-thirds of state opioid treatment authorities have adopted the change to offer counseling without threatening to withhold medication from patients who decline.
• ▪A survey of 241 clinics showed that more than 70% of responding clinics had adopted at least half of the recommended practice changes, including greater access to take-home medication.
• ▪The 2024 federal regulations made permanent the COVID-19 pandemic-era flexibilities allowing clinics to issue weeks' worth of take-home methadone medications.

Patient retention improvements

• ▪Mark Parrino, president of the American Association for the Treatment of Opioid Dependence, stated that more than 75% of programs providing more take-home medication saw a significant increase in treatment retention.
• ▪Dustin Mets, CEO of CompDrug, reported that the share of patients remaining in treatment three months after first seeking care increased by an average of 17% following the implementation of the changes.

Survey methodology limitations

• ▪Aaron Ferguson, a leader in the Liberate Methadone movement, argued that the Substance Abuse and Mental Health Services Administration-cited survey suffered from selection bias, likely representing clinics that enthusiastically embraced the changes.
• ▪Aaron Ferguson stated that clinics' efforts to solicit patient feedback focused primarily on compliant patients who were least likely to benefit from flexible policies.
• ▪The survey data cited by industry leaders represented only 241 clinics, which is just over 10% of opioid treatment programs nationwide.

Geographic disparities in implementation

• ▪Aaron Ferguson suggested that major geographic disparities exist, with clinics in progressive states like New York embracing the changes while those in conservative states largely ignore them.
• ▪Aaron Ferguson stated that most of the larger methadone providers have not been proactive in implementing the 2024 regulatory changes.

Methadone treatment system history

• ▪In 2020, during the COVID-19 pandemic, the Substance Abuse and Mental Health Services Administration first permitted clinics to issue weeks' worth of take-home medications to prevent disease spread.
• ▪Historically, methadone clinics typically required patients to attend in person each day to receive their doses, posing challenges for those with jobs, families, or long commutes.